IRVINE, Calif., July 26, 2017 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2017. Second Quarter and Recent Highlights: Sales grew 11 percent to $842 million; underlying1 sales increased 15 percent […]
Author: Ken Dropiewski
Boston Scientific (BSX) Announces Results For Second Quarter 2017
MARLBOROUGH, Mass., July 27, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.257 billion during the second quarter ended June 30, 2017. This represents growth of 6 percent on a reported basis and 7 percent on an operational basis (excludes the impact of changes in foreign currency exchange rates), all compared to […]
Spectranetics (SPNC) Secures FDA Approval of Stellarex Drug-Coated Balloon
COLORADO SPRINGS, Colo., July 26, 2017 (GLOBE NEWSWIRE) — The Spectranetics Corporation (NASDAQ:SPNC) today announced receipt of U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) of the Stellarex™ drug-coated balloon (DCB), designed to restore and maintain blood flow to the superficial femoral and popliteal arteries in patients with peripheral arterial disease […]
Researchers Prove Human Heart’s ‘Battery’ Has Multiple Backups
Newswise — COLUMBUS, Ohio – There’s good news when it comes to our heart’s sinoatrial node (SAN), the body’s natural pacemaker. Scientists at The Ohio State University Wexner Medical Center have shown the human SAN is hardwired with a backup system — three diverse regions of pacemakers acting as batteries and up […]
Bolton Medical Announces the First Implant in the TREO® Global Registry
Sunrise, Fla, July 21, 2017 – Today announced the first implant of the TREO Abdominal Stent Graft System in the TREO Registry: a Post-Market Surveillance Clinical Investigation that aims to assess long term real-world data of the TREO Technology in a Global, Prospective, Multicenter and Observational Study. The technology that will […]
Penumbra Schedules Second Quarter 2017 Earnings Release And Conference Call For August 8, 2017 At 4:30 PM Eastern Time
ALAMEDA, Calif., July 25, 2017 /PRNewswire/ — Penumbra, Inc.(NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2017 after market close on Tuesday, August 8, 2017 at 4:30 PM Eastern Time. A press release with second quarter 2017 financial results will be issued after market close […]
Corindus Vascular Robotics To Report Second Quarter 2017 Financial Results On August 8, 2017
WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that it will release financial and business results for the second quarter of 2017 after the close of trading on Tuesday, August 8, 2017. The Company’s management team will host a corresponding conference […]
Medtronic (MDT) First To Receive Health Canada Licence For MR-Conditional Cardiac Resynchronization Therapy-Defibrillators
BRAMPTON, Ontario, July 26, 2017 (GLOBE NEWSWIRE) — Medtronic Canada, a subsidiary of Medtronic plc, today announced it has received a Health Canada licence and is launching its first and only magnetic resonance imaging (MRI) conditional cardiac resynchronization therapy defibrillators (CRT-Ds) for heart failure. Heart failure causes or contributes to […]
SurModics (SRDX) Receives IDE Approval To Initiate Pivotal Trial Of The Surveil Drug-Coated Balloon
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate a pivotal clinical trial of the SurVeil™ drug-coated balloon (DCB). The randomized […]
BioCardia Completes Roll-In Cohort In Pivotal Phase III CardiAMP Heart Failure Trial
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced completion of treatment for the 10-patient roll-in cohort for the pivotal Phase III CardiAMP Heart Failure Trial. A pre-specified review of the 30-day outcomes in this cohort by the Data […]



